OCREVUS® (ocrelizumab) Pregnancy Registry

Do you have multiple sclerosis (MS) and are you pregnant? Then you may be able to take part in a global registry of women with MS who are pregnant and either have or have not received OCREVUS® (ocrelizumab) during or within 6 months before their pregnancy. Get in touch with a registry representative to learn more.

Contact Me

About pregnancy and multiple sclerosis

The effects of a particular medicine on the health of an unborn baby are often unknown because pregnant women are not usually included in clinical research studies to test a potential new medicine. Pregnancy registries aim to collect information that could help women and their healthcare providers make more informed decisions about using a particular medicine during pregnancy in the future.

Learn more about pregnancy & MS

What is the OCREVUS Pregnancy Registry?

The OCREVUS Pregnancy Registry is a global registry for women with MS who are pregnant and have or have not received OCREVUS (ocrelizumab). The purpose of this pregnancy registry is to learn more about the health of pregnant women who have or have not received ocrelizumab and the health of their babies. This will be done by monitoring participants throughout their pregnancy, followed by monitoring the health of their babies until they are at least 12 months old.

Because of this registry, pregnant women who are exposed to ocrelizumab in the future may have more information about how their pregnancies and babies may or may not be affected.

Learn more about the OCREVUS Pregnancy Registry

Have questions?

Have questions?

Visit the FAQs section for the answers to common questions that you may have about the OCREVUS Pregnancy Registry.


Am I eligible?

You may be able to take part in this registry if you are 18 years or older and pregnant, have MS, and:

1 have received ocrelizumab at any time since 6 months before your last menstrual period, or


2 have not received ocrelizumab or any other MS disease-modifying therapy, except glatiramer acetate, at any time since 6 months before your last menstrual period.

Contact me

Information for patients

Download the Information Booklet for pregnant women who have received OCREVUS (ocrelizumab)


If you were not exposed to OCREVUS, please click here to download the information booklet for pregnant woman who have not received OCREVUS.


Information for healthcare providers

Learn more about the OCREVUS Pregnancy Registry

How do I participate?

Fill out the contact form to have a registry representative contact you with more information on the registry

Call the registry's toll-free number 1 (833) 872-4370 and speak to a registry representative

Ask your healthcare provider to help you complete the contact form

For the latest important safety information, please refer to the full Prescribing Information and Medication Guide. This is not intended to replace discussions with your healthcare provider.

This site uses cookies including for the essential functioning of the site and for analytical purposes. For more information about these cookies and the choices you have to manage them, please view our Privacy Policy or visit the Interactive Advertising Bureau

By clicking through the website, we understand this means you have accepted our cookies.